Abstract

This article uses narrative accounts of women who are intended parents to show the health and financial implications of infertility treatments, underregulation, and lack of funding in the United States and abroad. It argues that providing access to infertility treatment and regulating for safety are necessary means of protecting the health of women diagnosed with infertility and women who, through the sale of their reproductive goods and services, are the catalysts to conception. Many moral ambiguities arise from the utilization of assistive reproductive technologies to treat infertility, requiring careful scrutiny of market and nonmarket values.